Drug Profile
Research programme: anticancer therapeutics - Braintree Laboratories
Alternative Names: BLI-600Latest Information Update: 04 Mar 2020
Price :
$50
*
At a glance
- Originator INRA Transfert
- Developer Braintree Laboratories
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in France
- 13 Mar 2006 Preclinical trials in Cancer in France (unspecified route)